AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

As part of his love-in with infrastructure, the Prime Minister is vowing to 'rip up the rules' and grant planning licences ...

How an agreement set up by the Tories and lauded by Labour fell victim to cost-cutting and UK curbs on drugs expenditure ...

THE Bank of England yesterday lowered interest rates from 4.75 per cent to 4.5, while halving its growth forecasts amid fears ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Q4 2024 Earnings Call Feb 06, 2025, 6:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants ...

Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

Pascal Soriot, chief executive of AstraZeneca, denied any rift with the Government over the decision, which it revealed ...

The boss of drugmaker AstraZeneca has said he was "very disappointed" with the firm’s move to scrap plans for a £450m vaccine plant in Liverpool, but insisted ...